Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Raw Materials (2018 - 2024)

RedHill Biopharma has reported Raw Materials over the past 7 years, most recently at $513000.0 for Q4 2024.

  • Quarterly Raw Materials fell 38.04% to $513000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $513000.0 through Dec 2024, down 38.04% year-over-year, with the annual reading at $513000.0 for FY2024, 38.04% down from the prior year.
  • Raw Materials was $513000.0 for Q4 2024 at RedHill Biopharma, down from $828000.0 in the prior quarter.
  • Over five years, Raw Materials peaked at $3.0 million in Q4 2021 and troughed at $513000.0 in Q4 2024.
  • The 5-year median for Raw Materials is $1.8 million (2020), against an average of $1.6 million.
  • Year-over-year, Raw Materials skyrocketed 68.08% in 2021 and then crashed 53.92% in 2023.
  • A 5-year view of Raw Materials shows it stood at $1.8 million in 2020, then skyrocketed by 68.08% to $3.0 million in 2021, then plummeted by 40.34% to $1.8 million in 2022, then crashed by 53.92% to $828000.0 in 2023, then tumbled by 38.04% to $513000.0 in 2024.
  • Per Business Quant, the three most recent readings for RDHL's Raw Materials are $513000.0 (Q4 2024), $828000.0 (Q4 2023), and $1.8 million (Q4 2022).